

# Sevin Turcan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2818920/publications.pdf>

Version: 2024-02-01

45  
papers

8,358  
citations

279701

23  
h-index

265120

42  
g-index

47  
all docs

47  
docs citations

47  
times ranked

12909  
citing authors

#	ARTICLE	IF	CITATIONS
1	IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature, 2012, 483, 474-478.	13.7	1,693
2	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 2012, 483, 479-483.	13.7	1,668
3	An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science, 2013, 340, 626-630.	6.0	1,014
4	Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature, 2019, 573, 532-538.	13.7	628
5	The mutational landscape of adenoid cystic carcinoma. Nature Genetics, 2013, 45, 791-798.	9.4	394
6	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. Nature Medicine, 2013, 19, 901-908.	15.2	388
7	Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nature Medicine, 2018, 24, 1192-1203.	15.2	359
8	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics, 2013, 45, 253-261.	9.4	324
9	Integrated genomic characterization of IDH1-mutant glioma malignant progression. Nature Genetics, 2016, 48, 59-66.	9.4	253
10	Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Science Translational Medicine, 2011, 3, 75ra25.	5.8	242
11	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget, 2013, 4, 1729-1736.	0.8	213
12	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nature Genetics, 2014, 46, 588-594.	9.4	144
13	5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget, 2013, 4, 1737-1747.	0.8	141
14	Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nature Genetics, 2018, 50, 62-72.	9.4	137
15	The $\alpha 10$ nicotinic acetylcholine receptor subunit is required for normal synaptic function and integrity of the olivocochlear system. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20594-20599.	3.3	121
16	An Integrated Systems Biology Approach Identifies TRIM25 as a Key Determinant of Breast Cancer Metastasis. Cell Reports, 2017, 20, 1623-1640.	2.9	96
17	Transcriptional diversity of long-term glioblastoma survivors. Neuro-Oncology, 2014, 16, 1186-1195.	0.6	69
18	Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Science Advances, 2020, 6, eaaz3221.	4.7	67

#	ARTICLE	IF	CITATIONS
19	Origin of Gliomas. <i>Seminars in Neurology</i> , 2018, 38, 005-010.	0.5	52
20	Remodeling of the Methylation Landscape in Breast Cancer Metastasis. <i>PLoS ONE</i> , 2014, 9, e103896.	1.1	43
21	Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. <i>OncoTargets and Therapy</i> , 2013, 6, 223.	1.0	38
22	RECK controls breast cancer metastasis by modulating a convergent, STAT3-dependent neoangiogenic switch. <i>Oncogene</i> , 2015, 34, 2189-2203.	2.6	34
23	IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. <i>Scientific Reports</i> , 2016, 6, 27569.	1.6	26
24	TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. <i>Neuro-Oncology</i> , 2021, 23, 76-87.	0.6	24
25	The Cochlear CRF Signaling Systems and their Mechanisms of Action in Modulating Cochlear Sensitivity and Protection Against Trauma. <i>Molecular Neurobiology</i> , 2011, 44, 383-406.	1.9	19
26	The cochlea as an independent neuroendocrine organ: Expression and possible roles of a local hypothalamicâ€“pituitaryâ€“adrenal axis-equivalent signaling system. <i>Hearing Research</i> , 2012, 288, 3-18.	0.9	19
27	Lack of nAChR Activity Depresses Cochlear Maturation and Up-Regulates GABA System Components: Temporal Profiling of Gene Expression in $\pm 9$ Null Mice. <i>PLoS ONE</i> , 2010, 5, e9058.	1.1	19
28	Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas. <i>Cancers</i> , 2019, 11, 1616.	1.7	17
29	From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas. <i>Cells</i> , 2021, 10, 1225.	1.8	17
30	Approaching Sites of Action of Temozolomide for Pharmacological and Clinical Studies in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1.	1.4	17
31	Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas. <i>Acta Neuropathologica Communications</i> , 2019, 7, 201.	2.4	13
32	Corticotropinâ€“releasing factorâ€“2 activation prevents gentamicinâ€“induced oxidative stress in cells derived from the inner ear. <i>Journal of Neuroscience Research</i> , 2010, 88, 2976-2990.	1.3	12
33	<i>MEOX2</i> homeobox gene promotes growth of malignant gliomas. <i>Neuro-Oncology</i> , 2022, 24, 1911-1924.	0.6	8
34	3D Whole-Brain Imaging Approaches to Study Brain Tumors. <i>Cancers</i> , 2021, 13, 1897.	1.7	7
35	Nuclei Isolation from Fresh Frozen Brain Tumors for Single-Nucleus RNA-seq and ATAC-seq. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	7
36	Multiplexed Isobaric Tagging Protocols for Quantitative Mass Spectrometry Approaches to Auditory Research. <i>Methods in Molecular Biology</i> , 2009, 493, 345-366.	0.4	6

#	ARTICLE	IF	CITATIONS
37	Changing paradigms in oncology: Toward noncytotoxic treatments for advanced gliomas. International Journal of Cancer, 2022, 151, 1431-1446.	2.3	6
38	MAPping the genomic landscape of low-grade pediatric gliomas. Nature Genetics, 2013, 45, 847-849.	9.4	5
39	Epigenetic Drugs and Their Immune Modulating Potential in Cancers. Biomedicines, 2022, 10, 211.	1.4	5
40	Phenotypic and molecular states of IDH1 mutation-induced CD24-positive glioma stem-like cells. Neoplasia, 2022, 28, 100790.	2.3	5
41	MINING FUNCTIONALLY RELEVANT GENE SETS FOR ANALYZING PHYSIOLOGICALLY NOVEL CLINICAL EXPRESSION DATA. , 2010, , 50-61.		3
42	The Magnifying GLASS: Longitudinal Analysis of Adult Diffuse Gliomas. Cell, 2020, 180, 407-409.	13.5	2
43	From anti-aging drugs to cancer therapy: is there a potential for sirtuin activators in gliomas?. Neuro-Oncology, 2021, 23, 3-5.	0.6	2
44	Clinical utility of solid tumor epigenetics. , 2021, , 425-446.		0
45	CBIO-20. HIGH LEVELS OF TERT CONFER SENSITIVITY TO THE DNA HYPOMETHYLATING AGENT DECITABINE (DAC) IN GLIOMAS. Neuro-Oncology, 2021, 23, vi31-vi31.	0.6	0